119 related articles for article (PubMed ID: 8195833)
1. In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria.
Seydel JK
J Chemother; 1993 Dec; 5(6):422-9. PubMed ID: 8195833
[TBL] [Abstract][Full Text] [Related]
2. Bacterial growth kinetics of Escherichia coli and mycobacteria in the presence of brodimoprim and metioprim alone and in combination with sulfamerazine and dapsone (VI).
Seydel JK; Wempe EG; Rosenfeld M
Chemotherapy; 1983; 29(4):249-61. PubMed ID: 6347548
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo experiments with the new inhibitor of mycobacterium leprae brodimoprim alone and in combination with dapsone.
Seydel JK; Wempe EG; Rosenfeld M; Jagannathan R; Mahadevan PR; Dhople AM
Arzneimittelforschung; 1990 Jan; 40(1):69-75. PubMed ID: 2187440
[TBL] [Abstract][Full Text] [Related]
4. Preparation and biological activity of new substituted antimalarial diaminodiphenylsulfones.
Pieper H; Seydel JK; Krüger G; Noll K; Keck J; Wiese M
Arzneimittelforschung; 1989 Sep; 39(9):1073-80. PubMed ID: 2686656
[TBL] [Abstract][Full Text] [Related]
5. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
Dhople AM; Ortega I; Seydel JK; Gardner GD
Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
[TBL] [Abstract][Full Text] [Related]
6. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy against M. leprae?
Seydel JK; Wempe EG
Int J Lepr Other Mycobact Dis; 1982 Mar; 50(1):20-30. PubMed ID: 7042611
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans.
Dhople AM
J Antimicrob Chemother; 2001 Jan; 47(1):93-6. PubMed ID: 11152437
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of the folate blocker diaminodiphenylsulfone (dapsone, DDS) studied in E. coli cell-free enzyme extracts in comparison to sulfonamides (SA).
Seydel JK; Richter M; Wempe E
Int J Lepr Other Mycobact Dis; 1980 Mar; 48(1):18-29. PubMed ID: 6988345
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
Dhople AM
Int J Antimicrob Agents; 1999 Aug; 12(4):319-23. PubMed ID: 10493608
[TBL] [Abstract][Full Text] [Related]
10. Activity of the combination of isoniazid, protionamide and dapsone against Mycobacterium leprae and some other mycobacteria.
Pattyn SR; Portaels F; Van Loo G; Van den Breen L
Arzneimittelforschung; 1981; 31(12):2155-7. PubMed ID: 7037011
[TBL] [Abstract][Full Text] [Related]
11. Dapsone resistance in Mycobacterium leprae.
Gillis TP; Williams DL
Lepr Rev; 2000 Dec; 71 Suppl():S91-5. PubMed ID: 11201896
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antileprosy activity of some dialkyldithiocarbamates.
Makarov V; Riabova OB; Yuschenko A; Urlyapova N; Daudova A; Zipfel PF; Möllmann U
J Antimicrob Chemother; 2006 Jun; 57(6):1134-8. PubMed ID: 16595643
[TBL] [Abstract][Full Text] [Related]
13. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.
Cambau E; Carthagena L; Chauffour A; Ji B; Jarlier V
Clin Infect Dis; 2006 Jan; 42(2):238-41. PubMed ID: 16355335
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of bacterial adhesion by sub-inhibitory concentrations: brodimoprim vs trimethoprim.
Braga PC; Piatti G; Limoli A; Santoro M; Gazzola T
J Chemother; 1993 Dec; 5(6):447-52. PubMed ID: 8195836
[TBL] [Abstract][Full Text] [Related]
15. Dapsone resistance does not appear to be associated with a mutation in the dihydropteroate synthase-2 gene of Mycobacterium leprae.
Gillis TP; Williams DL
Indian J Lepr; 1999; 71(1):11-8. PubMed ID: 10439322
[TBL] [Abstract][Full Text] [Related]
16. Multiple docking analysis and
Halder ST; Dhorajiwala TM; Samant LR
Int J Mycobacteriol; 2019; 8(3):229-236. PubMed ID: 31512598
[TBL] [Abstract][Full Text] [Related]
17. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
Forsch RA; Queener SF; Rosowsky A
Bioorg Med Chem Lett; 2004 Apr; 14(7):1811-5. PubMed ID: 15026078
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, antibacterial activity and docking study of some new trimethoprim derivatives.
Rashid U; Ahmad W; Hassan SF; Qureshi NA; Niaz B; Muhammad B; Imdad S; Sajid M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5749-5753. PubMed ID: 28327306
[TBL] [Abstract][Full Text] [Related]
19. Sulfa and trimethoprim-like drugs - antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors.
Capasso C; Supuran CT
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):379-87. PubMed ID: 23627736
[TBL] [Abstract][Full Text] [Related]
20. Sub-inhibitory concentrations of brodimoprim inhibit adhesion of E. coli to human uroepithelial cells.
Braga PC; Piatti G; Reggio S
Drugs Exp Clin Res; 1992; 18(6):233-7. PubMed ID: 1478162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
